CIK 0001728117
- Non-accelerated filer
- Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 475461709
- Phone
- +1 858-684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 6 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-24 | Peterson Caryn Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +5,800,051 | 5,800,051 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −506,250 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −440,000 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −375,000 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −125,000 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −157,500 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −157,500 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −126,667 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −21,167 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −18,834 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −22,784 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −9,167 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −32,334 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +506,250 | 506,250 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +440,000 | 440,000 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +375,000 | 375,000 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +126,667 | 126,667 |
Page 1 of 3 · 53 trades